Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

Srinivasa, B.; Lalkota, Bhanu Prakash; Badarke, Girish; Hazarika, Diganta; Nasiruddin, Mohammad; Sapkota, Sulav; Khanderia, Mansi; Tousif, Devale; Rao, Raghavendra; Ram, Amritanshu; Patil, Shekar; Naik, Radheshyam

doi:10.1177/1179554918782475

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diversity of the unique genetic profile of the Indian population is also reflected in terms of patient population, sample size, disease characteristics etc. In a previous study from India on metastatic breast cancer patients, 60% of the patients were premenopausal 18 . A high proportion of Indian women present with denovo metastatic disease.…”

Section: Discussionmentioning

confidence: 94%

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population

Agrawal

Goyal

Agarwal

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2− MBC). Several randomized trials have shown the benefits of this combination, however, real world evidence in the Indian patients is warranted. The present study reports the largest real world multicentric data from Indian population on the use of Palbociclib in HR+/HER2− MBC. A multicentric study on the HR+/HER2− MBC patients who received palbociclib with hormonal agent (Aromatase inhibitors/Fulvestrant) between February 2017 and May 2020 was conducted. Clinical and demographic information and survival data was retrieved from the Hospital medical records. Among a total of 188 patients, 57% patients were premenopausal and 17% patients had bone only disease. Altogether, 115 (61%) patients received palbociclib with Aromatase inhibitors in the first line whereas 73 (39%) patients received it in the second line with Fulvestrant. The median follow up period with advanced disease was 13 months. The median progression free survival in the first line and second line was 20.2 months and 12 months, respectively (p-value < 0.0001). The objective response rate was 80% and 47.9% in first and second lines, respectively. Dose interruptions/ discontinuation were done in 14.9% and 2.7% patients in the first and second lines, respectively. In terms of toxicity, 10% patients had grade 3–4 adverse events. The present real world data of the use of palbociclib in Indian population suggests similar effectiveness to previously published real world evidences and has been adapted as the standard of care in the first and second line treatment of HR+/HER2− MBC.

show abstract

Section: Discussionmentioning

confidence: 94%